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1. Introduction 
Platelet surface glycoconjugates have been suggested 
to play roles in the major biological functions of this 
cell, namely aggregation and adhesion [ 141. Bosmann 
[5] first showed that platelet suspension as well as 
plasma membrane fraction possessed sialyltransferase 
activity which would play a role in platelet aggregation. 
In fact, a parallel inhibition of aggregation and sialyl- 
transferase activity by aspirin [5,6] and an apparent 
stimulation of sialyltransferase activity with various 
platelet aggregating agents such as collagen, epinephrin 
and ADP plus fibrinogen [7] have been noted, while 
cancer patients with a high incidence of thrombosis 
have markedly elevated levels of platelet sialyltransfer- 
ase activity [6]. Despite the possible functional signi- 
ficance of the above studies, the presence of ectosial- 
yltransferase activity at the human platelet surface has 
not been rigorously defined. This is due to possible 
errors introduced into most assay systems by: 
(i) Precursor degradation and intracellular utilisation 
of the free radioactive sialic acid: 
(ii) The liberation of intracellular enzymes as a result 
of cell lysis during the assay; 
(iii) Phagocytosis of added exogenous acceptors [8]. 
Using exogenous non-phagocytosable acceptors [9] 
and the methodology developed to prove the presence 
of ectoglycosyltransferases at the surface of other cell 
types [ lo,1 11, we demonstrate here that the human 
blood platelet exhibits ectosialyltransferase activity 
and that the major endogenous acceptor is the plama 
membrane glycoprotein GP IIb. 
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2. Materials and methods 
2.1. Preparation of platelets and platelet homogenates 
Blood from normal human donors was collected in 
plastic containers using an acid-citrate-dextrose 
(ACD) anticoagulant as in [12]. The platelets were iso- 
lated as in [ 121 and resuspended in 10 mM Tris-HCI 
(pH 7.4), containing 0.154 M NaCl, 1 mM EDTA, 
0.3% (w/v) bovine serum albumin and 5 mM glucose. 
Lactate dehydrogenase activity was measured [13] as 
a control of cell lysis. Platelet homogenisation was per- 
formed at 10” platelets/ml by sonication for 3 X 1 min 
using a MSE ultrasonicator (wavelength 14.5 pm) 
under constant cooling at 4°C. 
2.2. Preparation of acceptors 
Fetuin was purchased from Sigma (St Louis USA). 
Desialylation was performed by mild acid hydrolysis 
(0.1 N trifluoroacetic acid, 8O”C, 35 min) and effec- 
tive desialylation was checked by gas-liquid chroma- 
tography. Asialofetuin was coupled either to Sepharose 
4B (Pharmacia, Sweden) by the CNBr method [ 141 or 
to Biogel P-300 (Biorad, USA) and Ultrogel AcA 44 
(Industrie Biologique Franpaise, France) [ 151. 
2.3. Standard sialyltransferase assays 
Washed platelets were resuspended in the washing 
buffer as above. AU inbubations were performed in 
this buffer. A standard assay consisted of 100 ~1 
final vol. containing 10’ platelets, 100 pg asialofetuin 
and 2 PM CMP-[‘4C]NeuAc (NEN, FRG; spec. act. 
235 mCi/mmol). When insolubilised acceptors were 
used, 100 ,ul suspension containing 0.5 mg fixed asia- 
lofetuin/ml beads was employed; the assay volume was 
200 ~1 and contained 6 X lOa platelets. After incuba- 
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tion at 37°C for 1 11, the integrity of the remaining 
substrate was examined after the separation of free 
[‘“Cl NeuAc from CMP-[ 14C] NeuAc by paper chro- 
matography in absolute ethanol, 1 M ammonium ace- 
tate (7 :3, v/v) for 24 Ii. 
2.4. De termination of radiouc tivicy incorporated in to 
endogenous and exogenous accep tars 
The radioactivity incorporated into phosphotung- 
stic acid-precipitable material was measured as in [9]. 
The radioactivity incorporated into the exogenous 
acceptors was determined by subtracting the value 
obtained when the assay was performed in the absence 
of added acceptors. When insolubilised acceptors were 
used, the separation of the coupled beads from plate- 
lets was achieved by low speed centrifugation in a 32%’ 
metrizamide medium [9]. Acid-precipitable or -insol- 
uble material was collected and washed on glass fiber 
filters (Whatman GF 83) then the radioactivity deter- 
mined in a scintillation liquid. 
2.5 . Plutelet desiulylation 
Platelets were resuspended in washing buffer in the 
presence of IO mM CaCl* at 10’ platelets/ml. Neur- 
aminidase (Vibrio cholcrae; Behringwerke, FRG) was 
added to 10 units/ml final cont. and the platelet sus- 
pension incubated for 1 h at 37°C. The treated plate- 
lets were washed twice in the washing buffer (without 
CaCl,) before use. 
2.6. Sodium dodecylsulphate --polvacrylamide gel 
electrophoresis (SDS-PAGE) 
Following incubation with CMP-[‘4C]NeuAc but 
in absence of exogenous acceptor, the platelets were 
sedimented and resuspended at IO’ platelets/ml in 
0.01 M Tris-HC1 (pH 7.4), 0.154 M NaCl, 3 mM EDTA 
and 5 mMN-ethylmaleimide. The SDS-PAGE pattern 
of platelet surface proteins was obtained by labelling 
of platelet suspensions with 12’1 by the lactoperoxi- 
dasecatalysed procedure [ 161. The ‘2SI-labelled plate- 
lets were washed and solubilised by heating at 100°C 
for 5 min in 2% (w/v) SDS. SDS-PAGE was performed 
using 7--l 2% exponential acrylamide gradient slab gels 
and the buffer systems in [ 171. A constant proportion 
(2.7%) of NJ’-methylene-his-acrylamide to acryl- 
amide was maintained throughout the gel. Samples 
containing 2000 cpm 14C or 10 000 cpm 1251 were 
applied to the gel, each sample being analysed with or 
without disulphide bond reduction which was per- 
formed by incubating the SDS-solubilised platelets 
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for 1 h at 37°C in the presence of 5% (v/v) 2mercap- 
toethanol. Molecular weight determinations were made 
using Bio-Rad protein standards (Bio-Rad, USA). Elec- 
trophoresis was performed overnight at a constant 25 V. 
The proteins were located by Cootnassie blue staining 
[ 16]> the gels dried and direct autoradiography per- 
formed using Kodak X-Omat MA films (1 month, 
room temp.). The exposed films were developed and 
scanned. 
3. Results and discussion 
3.1. Platelet sialyltransferase activity 
Preliminary studies were performed using platelet 
suspensions and soluble asialofetuin as an exogenous 
added acceptor. Fig.lA shows a time-dependent incor- 
poration of [14C]NeuAc both into the asialofetuin and 
by the cells. Although CMP-NeuAc hydrolase activity 
is detected as shown on fig.1 B, the incorporation was 
linear for at least 2 h. However, it has to be noted that 
since : 
(i) Intracellular utilisation of the generated free sialic 
has not been inhibited : 
(ii) The platelet suspensions contain a certain percent- 
age of broken cells; 
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Fig.1. Kinetics of transfer of [14C]NeuAc and of CMP--[‘4C]- 
NeuAc degradation by whole platelet suspensions. Incubations 
were pcrforrncd as described in the standard assay with 2 bM 
CMP- [‘4CJNeuAc. (A) Transfer of [‘4C]NeuAc to endoge- 
nous acceptors (0) and to asialofetuin (0). (B) Integrity of 
CMP-[“C]NeuAc (0) and [‘*C]NeuAc appearance (0) were 
measured for each point. 
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(iii) Phagocytosis of soluble asialofetuin may occur; 
the radioactivity bound to the cells and to the exoge- 
nous acceptor may not be related to ectosialyltransfer- 
ase activity. Consequently, experimental procedures 
were developed to avoid these main causes of errors 
and demonstrate the presence of sialyltransferase activ- 
ity at the surface of human blood platelets. 
3.2. Demonstration for ectosialyltransferase active on 
exogenous and endogenous acceptors 
Non-phagocytosable acceptors were used as in [9]. 
Initial studies showed that asialofetuin coupled to 
Sepharose 4B was a poor acceptor (table 1) despite 
the fact that uncoupled asialofetuin readily accumu- 
lated radioactivity (fig.]). However, increased incor- 
poration was obtained when asialofetuin was coupled 
to Ultrogel AcA 44 or Biogel P 300 (table 1A). A 
number of control experiments determined that this 
incorporation did not result from a non-specific ad- 
sorption of radioactive material by the beads (table 1 B). 
Incubation of CMP- [ 14C] NeuAc with non-coupled 
Table 1 
Incorporation of radioactivity into non-phagocytosable 
insoluble acceptors 
_ 
Incu- Radioactive NeuAc 
bation transferred to 
time asialofetuin on 
(min) coupled beads (cpm) 
(A) Standard assay 
+ Sepharose 4B 
coupled asialofetuin 60 
+ Ultrogel AcA 44 
coupled asialofetuin 60 
+ Biogel P 300 
coupled asialofetuin 60 
65 
350 
300 
(B) Standard assay 
+ Ultrogel AcA 44 
coupled asialofetuin 0 30 
- Coupled beads + 
uncoupled Ultrogel 
AcA 44 60 70 
- Cells + Ultrogel 
AcA 44 coupled 
asialofetuin 60 50 
Incubations were performed as in the standard assay with 2 PM 
CMP-[“‘C]NeuAc. (A) Transfer of radioactivity to asialo- 
fetuin coupled to different support beads; (B) estimation of 
the non-specific adsorption to the beads. The IabeIIed beads 
were separated from the platelet suspension by centrifugation 
in a metrizamide medium as detailed in section 2 
beads and platelets or with asialofetuin beads and no 
cells resulted in little adsorption of radioactivity. This 
procedure allows the exclusion of a sialylation process 
due to phagocytosis of the acceptor. 
To assign the radioactivity recovered with the cells 
to ectosialyltransferase activity, hydrolysis of the pre- 
cursor and entry of free labelled sugar into the cell 
must be brought to a negligible level. As free NeuAc 
has been shown to enter cells [ 181, we tested that a 
1 OOO-fold excess of unlabelled NeuAc did not reduce 
the radioactivity bound to the platelets, proving that 
labelling of the cells was not due to entry of labelled 
NeuAc. 
To determine whether the observed sialyltransferase 
activity either on exogenous insolubilized or endoge- 
nous acceptors could be due to the liberation of intra- 
cellular enzymes from the small percentage of broken 
cells, mixtures containing definite proportions of in- 
tact and broken platelets were incubated with CMP- 
[‘“Cl NeuAc in standard conditions [ I “1. Provided 
isotopic dilution brought by the release of endoge- 
nous precursors does not occur [20], extrapolation to 
a hypothetical level of 0% lysed platelets should repre- 
sent the ectosialyltransferase activity. In the case of 
human platelets, the intracellular pool of CMP-NeuAc, 
if any, is not high enough to cause isotupic dilution 
of the labelled precursors as it has been demonstrated 
that increasing amounts of post-microsomal superna- 
tant do not affect the amount of radioactivity incor- 
porated by the platelet. Fig.2 shows that the extrapo- 
lation to 0% of broken cells leads to a significant incor- 
poration of radioactivity by the platelsts (fig.2A) and 
into the insolubilized acceptor (fig.2B 1 resulting from 
an ectosialyltransferase activity. 
These extrapolations of thes sialyltransferase activ- 
ity to 100% intact cells clearly demonstrates that 
there is an ectosialyltransferase active both on exoge- 
nous and endogenous acceptors. 
In addition, if prior to incubation with CMP- 
[l”C]NeuAc, the platelet surface glycoconjugates are 
desialylated under conditions not affecting cell viabil- 
ity, the ectosialyltransferase activity appears to be 
stimulated (-g-fold) by the presence of an increased 
number of membranous acceptors at the quter surface 
of the platelet. 
3.3. Identification of the endogenous acceptors 
As shown in fig.3, several bands of radioactivity 
were observed when [14C]NeuAc labelled platelets 
were analysed (fig.3b,d), on analysis of the 14C-labelled 
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Fig.2. Sialyltransferase activity of human platelet suspension 
as a function of the percentage of broken cells. Mixtures con- 
taining various known proportions of whole platelet suspen- 
sions and platelet homogenates were incubated for 60 min as 
in section 2, with 2 /JM CMPF[‘4C]NeuAc. (A) Transfer of 
[14C]Ne~Ac was measured on endogenous acceptors (0). (B) 
Transfer of [ “C]NeuAc onto asialofctuin coupled to Ultrogel 
AcA 44 (0). The arrow on the lower scale indicates the pcr- 
centaye of broken platelets in the stock platelet suspension 
as measured by the lactate dchydrogenase activity. 
platelets, the most prominently labelled compound 
showing the characteristic mobility of GP IIb as iden- 
tified by a parallel run with I” I-labelled membrane 
proteins (fig.3a,c). This is a surface-oriented membrane 
glycoprotein with M, - 142 000, which on reduction 
yields an o-subunit of 132 000 M, and a smaller P-sub- 
unit of 23 000 M, [ 161. Note that <lO% of the total 
radioactivity bound to the cell is associated to glyco- 
lipids as assayed by a Folch extraction [21]. Our data 
illustrates that under the assay conditions used GP 
IIb is the major native endogenous acceptor for the 
platelet ectosialyltransferase nzyme. 
4. Conclusions 
We have provided evidence that ectosialyltransfer- 
ase activity is present at the external surface of plate- 
lets. We have taken into account the criteria established 
[8] in detecting ectoglycosyltransferase activities in 
whole cell suspensions. We have thus eliminated: 
(i) Possible phagocytosis of the acceptor; 
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f:ig.3. Identification ofendogenous membrsnc glycoprotein 
acceptors for platelet ectosialyltransferase activity. Platelets 
were either incubated with CMP-[‘4C]Ne~Ac under the 
standard assay conditions (b,d) or their surface proteins were 
labelled with lz51 using the lactoperosidasrcatal~~sed proce- 
dure (a~). The labellcd platelet proteins were then separated 
by SDS~PAGI: as in section 2. Samples were electrophoresed 
both in the absence of disulphide bond reduction (a.b) and 
following dirulphide bond reduction (c,d). Ib, Ilb, IIIa corrc- 
spond to the major surface glycoproteins of human blood 
platelets. 
(ii) Intracellular utilisation of free radioactive NeuAc 
generated by hydrolysis of the substrate: 
(iii) The action ofintracellular enzymes liberated from 
broken platelets as major contributors to our 
findings. 
The analysis of the sialylated membrane consti- 
tuents by SDS-PAGE reveals that the major ‘ecto- 
acceptor’ is the glycoprotein lib, Bosmann [5] was 
the first to propose a functional role for ectosialyl- 
transferase nzymes during platelet aggregation. GP 
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IIb is missing or severely decreased in platelets from 
patients with Glansmann’s thrombasthenia [2,22], 
a bleeding disorder resulting from a defect in plate- 
let aggregation. Whether the fact that GP 1Ib is a 
sialyltransferase acceptor related to the thrombas- 
thenic platelet aggregation defect is unknown, but 
warrants further study. 
Acknowledgements 
This research was supported in part by grants from 
the CNRS (Laboratoire AssociC no. 217: Relation 
structure-fonction des constituants membranaires) 
and from INSERM (Contrat de recherche libre no. 
78-I 1942). B. B. received a fellowship from the 
Delegation G&r&ale a la Recherche Scientifique et 
Technique. The authors are indebted to Professor 
Goudemand (CRTS, Lille) for providing a continous 
supply of blood from normal human donors. We also 
thank Professor Bernard Fournet (Lille) for the gas- 
liquid chromatographic analyses. 
References 
111 
121 
[31 
Mester, L., Szabados, L., Born, C. V. R. and Michal, 1:. 
(1972) Nature New Biol. 236, 213-214. 
Nurden, A. T. and Caen, J. P. (1979) Semin. Hematol. 
16,234-250. 
Greenberg, J. H., Packham, M. A., Cazenave, J. P., 
Reimers, H. J. and Mustard, J. F. (1975) Lab. Invest. 
32,476-484. 
[4] Okumura, T. and Jamieson, G. A. (1976) Thrombosis 
Res. 8, 701~-706. 
(51 Bosmann. H. B. (1972) Biochim. Biophys. Acta 279, 
4566474. 
[6] Scialla, S. J., Speckart, S. F., Haut, M. J. and Kimball, 
D. B. (1979) Cancer Res. 39, 2031-2035. 
[7] Wu, K. K. and Ku, C. S. L. (1978) Thrombosis Rcs., 
13,183-192. 
[8] Keenan, T. W. and Morre, D. J. (1975) FEBS Lett. 55, 
8-13. 
[9] Cacan, R.,Verbert, A. and Montreuil, J. (1976) FEBS 
Lett. 63, 1022106. 
[lo] Verbert, A., Cacan, R. and Montreuil, J. (1976) Eur. J. 
Biochem. 70,49-53. 
[ II] Verbert, A., Cacan, R., Debeire, P. and Montreuil, J. 
(1977) FEBS Lett. 74, 234-238. 
[ 121 Caen, J. P., Nurden, A. T., Jeanneau, C., Michel, H., 
Tobelem, G., LevyToledano, S., Sultan, Y., Valensi, 
1:. and Bernard, J. (1976) J. Lab. Clin. Med. 87, 
5866596. 
[ 131 Wrobleski, R. and Ladues, J. S. (1955) Proc. Sot. Exp. 
Biol. Med. 90,210-213. 
1141 March, S. C., Parikh, 1. and Cuatrecasas, P. (1974) 
Anal. Biochem. 60, 147-152. 
[ 15 ] Weston, P. D. and Avrameas, S. (1971) Biochem. Bio- 
phys. Res. Commun. 45,1574-1580. 
[ 161 Phillips, D. R. and Poh Agin, P. (1977) J. Biol. Chem. 
252,2120-2126. 
[17] Laemmli, U. K. (1970) Nature 227,680-685. 
[ 181 Hirschberg, C. B., Goodman, S. R. and Green, C. 
(I 976) Biochemistry 15, 3591-3599. 
[ 191 Struck, D. K. and Lennarz, W. J. (1976), J. Biol. Chem. 
251,2511-2519. 
[20] Hoflack, B., Cacan, R., Montreuil, J. and Verbert, A. 
(1979) Biochim. Biophys. Acta 568, 3488356. 
[21] Folch, J., Less, M. and Sloane-Stanely, G. H. (1957) 
J.Biol.Chem.226,497. 
[ 221 Phillips, D. R. and Poh Agin, P. (1977) J. Clin. Invest. 
60,535-545. 
281 
